Loading the section
Closing prices for 09 October 2026
Next earnings report: none scheduled in the next five weeks · Earnings calendar
The series is stated in the current share scale after splits; dividends are not included in the price
Roivant Sciences Ltd. trades on Nasdaq under the ticker ROIV. The company belongs to the Health care sector. The trading history on this page starts on 08 December 2020.
Over the past 52 weeks ROIV has traded between 15.90 $ and 42.50 $. As of 09 October 2026 the price stood 73.46 % of the way from the 52-week low to the high.
Over one year ROIV shares rose 121.09 %; over six months they rose 25.63 %. Volatility over 90 days is 44.95 %. Dividends are not included: this is price change only, as of 09 October 2026.
The company reported a loss for the latest fiscal year, so a price-to-earnings ratio is not calculated. Price to sales is 2,999, above the sector median of 3.9. Price to book is 5.5, above the sector median of 2.4. Calculated from reports for the period ending 31 March 2026.
| Date | Open | High | Low | Close | Volume, shares |
|---|---|---|---|---|---|
| 09 October 2026 | 34.24 | 35.59 | 34.15 | 35.44 | 6M |
| 08 October 2026 | 34.28 | 34.56 | 33.32 | 34.21 | 6M |
| 07 October 2026 | 35.22 | 35.49 | 34.63 | 34.75 | 6M |
| 06 October 2026 | 35.86 | 36.34 |
Based on the fiscal year ended 31 March 2026
The sector median covers every company in the sector on the US market, loss-making ones included.
Roivant buys shelved drugs from large companies and takes them to approval through separate subsidiaries.
A large pharmaceutical company often shelves a promising molecule not because it is bad but because the market is small by its standards. Roivant buys such programmes cheaply and builds a separate company around each, with its own team motivated by that one drug's outcome.
The model has been proved by sales: one subsidiary holding a drug for inflammatory bowel disease was sold to a large pharmaceutical company for a sum that changed the whole group's position. Hence a large cash balance and funding for the remaining programmes without issuing shares. Risks: trial outcomes and the certainty that some programmes will not reach the market. The company pays no dividend.
Address:7TH FLOOR, 50 BROADWAY, LONDON, SW1H 0DB
ROIV has a return on equity of −6.62 %, above the sector median of −41.68 %. Return on assets is −5.25 %, above the sector median of −32.11 %.
| 1.2B |
| PFEPfizer, Inc. | 28.18 | +1.28 % | 929M |
| ABTAbbott Laboratories | 99.60 | +1.13 % | 921M |
| BMYBristol-Myers Squibb Company | 59.12 | −0.77 % | 714M |
| REGNRegeneron Pharmaceuticals, Inc. | 746.54 | +0.94 % | 555M |
| 34.75 |
| 35.53 |
| 6M |
| 05 October 2026 | 35.98 | 36.33 | 35.25 | 35.78 | 6M |
| 02 October 2026 | 35.61 | 36.00 | 35.19 | 35.72 | 4M |
| 01 October 2026 | 36.35 | 36.79 | 35.44 | 35.50 | 3M |
| 30 September 2026 | 36.77 | 36.96 | 36.23 | 36.57 | 5M |
| 29 September 2026 | 37.03 | 37.35 | 35.75 | 36.50 | 7M |
| 28 September 2026 | 35.65 | 37.25 | 35.28 | 36.98 | 7M |
| 25 September 2026 | 35.98 | 36.19 | 35.52 | 35.80 | 7M |
| 24 September 2026 | 36.64 | 36.75 | 35.91 | 36.13 | 6M |
| 23 September 2026 | 38.00 | 38.47 | 36.78 | 36.82 | 9M |
| 22 September 2026 | 38.73 | 39.17 | 38.11 | 38.22 | 7M |
| 21 September 2026 | 39.02 | 39.90 | 38.72 | 38.99 | 6M |
| 18 September 2026 | 40.11 | 40.71 | 39.72 | 39.77 | 32M |
| 17 September 2026 | 40.45 | 40.97 | 39.50 | 39.98 | 8M |
| 16 September 2026 | 39.77 | 40.45 | 39.17 | 39.57 | 6M |
| 15 September 2026 | 41.14 | 41.14 | 39.22 | 39.50 | 8M |
| 14 September 2026 | 40.64 | 41.60 | 40.44 | 41.02 | 8M |